Home
Team
Blog
Experts
Careers
Projects
Code of Conduct
Press
Publications
Contact Us
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
Would you use R2CHOP to treat DLBCL based on the results of the E1412 study?
Related Questions
How would you manage a patient with history of follicular lymphoma treated with Bendamustine-Rituximab who now has a new FDG avid lesion that is biopsy proven CD30 positive CD20 negative DLBCL?
How do you approach patients with a history of lymphoma in remission who are in need of immunosuppressive (e.g. TNF blockers, 6MP) or other therapies (e.g. JAK inhibitors) for autoimmune disease that have been linked with the development of lymphoma?
How do you choose your systemic treatment for primary mediastinal grey zone lymphomas?
In a patient newly diagnosed with mantle cell lymphoma who has focal intracerebral disease and has received SRS, what is the benefit to adding a BTK-inhibitor such as ibrutininb to chemotherapy?
Would you offer rituximab maintenance for 2 years after a successful response to induction in a patient with splenic marginal zone lymphoma?
How would you dose ABVD for classical Hodgkin lymphoma for a patient on hemodialysis?
How would you manage a stage IE DLBCL of the stomach, non-germinal center type by IHC, and Ki-67 of 70%, but negative for double/triple hit by FISH?
How do you treat a low-grade B-cell lymphoma with plasmacytic differentiation (Waldenstrom's) confined to the CNS?
How would you manage Stage IE DLBCL of the breast?
What chemotherapy, if any, would you offer for an elderly patient with congestive heart failure with completely excised Stage I classical Hodgkin lymphoma?
